Literature DB >> 15578191

Impaired mucosal regeneration in neonatal necrotising enterocolitis.

Daniela Vieten1, Anthony Corfield, Daniel Carroll, Pramila Ramani, Richard Spicer.   

Abstract

Necrotising enterocolitis (NEC) remains an overwhelming gastrointestinal (GI) emergency in premature infants, with an annual incidence of 350 cases and a mortality of 23% in the United Kingdom. The aetiology of NEC is multifactorial and its pathogenesis poorly understood. It is characterised by severe necrotic damage to the intestine. Mucus is an adherent, viscoelastic gel layer protecting the delicate underlying epithelium from lumenal aggressors such as digestive enzymes and bacterial toxins. The group of trefoil factor peptides (TFF1-3) are part of the protective mechanism operating in the intestinal mucosa and play a fundamental role in epithelial protection, repair, and restitution. These secreted peptides have been identified in a site-specific pattern in the GI mucosa, and their expression has been shown to be upregulated in early stages of mucosal repair. The role of trefoil peptides in neonatal mucosal protection has not been well investigated. Impaired mucosal regeneration due in part to failure of upregulation of TFF expression may contribute to the pathogenesis of NEC. The aim of this study was to investigate TFF1-3 mRNA expression and to identify the gene product in the GI tracts of normal neonatal controls and infants with NEC. Parents of all babies having a laparotomy in the neonatal period (defined as up to 44 weeks' gestation) and bowel resection were approached for written consent. Bowel samples were fixed in formalin and then embedded in paraffin in an RNAse-free manner. In situ hybridisation and immunohistochemistry were performed to examine the pattern of trefoil mRNA expression and to localise the peptides in the neonatal GI tract. Forty neonatal bowel specimens were examined. Twelve patients had NEC, eight were recovering from NEC, and 20 control specimens were obtained. TFF1 and TFF2 mRNA expression were not detected in the majority of NEC specimens, and there was a relative downregulation of TFF3 expression in 83% of NEC patients. TFF1 and TFF2 expression were noted in the recovery phase from NEC. Immunohistochemistry revealed a decrease in TFF3 gene product in sites adjacent to mucosal damage secondary to NEC. In acute NEC there was no apparent expression of TFF1 and 2 protein. In the group of patients recovering from NEC, TFF1 and 2 expression were seen in association with regenerative changes in the mucosa. Previous data has shown TFF1-3 to be upregulated in the acute phase response to mucosal injury in the gut. Trefoil peptides have been shown to promote epithelial cell migration and protect against apoptosis. Our results suggest that there is a lack of TFF expression in response to NEC in the premature gut. This may lead to impaired restitution of the mucosa and contribute to the cascade of bowel necrosis and generalised sepsis characteristic of NEC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578191     DOI: 10.1007/s00383-004-1312-6

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  26 in total

Review 1.  Review article: healing after inflammatory injury--coordination of a regulatory peptide network.

Authors:  D K Podolsky
Journal:  Aliment Pharmacol Ther       Date:  2000-04       Impact factor: 8.171

Review 2.  Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides.

Authors:  D K Podolsky
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

3.  Expression of intestinal trefoil factor in developing rat intestine.

Authors:  J Lin; I R Holzman; P Jiang; M W Babyatsky
Journal:  Biol Neonate       Date:  1999-08

Review 4.  Peptides and gastrointestinal mucosal integrity.

Authors:  R J Playford
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

Review 5.  Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts.

Authors:  Wei Hsueh; Michael S Caplan; Xiao-Wu Qu; Xiao-Di Tan; Isabelle G De Plaen; F Gonzalez-Crussi
Journal:  Pediatr Dev Pathol       Date:  2002-11-11

6.  Coordinated localisation of mucins and trefoil peptides in the ulcer associated cell lineage and the gastrointestinal mucosa.

Authors:  R J Longman; J Douthwaite; P A Sylvester; R Poulsom; A P Corfield; M G Thomas; N A Wright
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

7.  Biliary epithelial trefoil peptide expression is increased in biliary diseases.

Authors:  G Srivatsa; A S Giraud; M Ulaganathan; N D Yeomans; C Dow; A J Nicoll
Journal:  Histopathology       Date:  2002-03       Impact factor: 5.087

8.  Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein.

Authors:  H Kindon; C Pothoulakis; L Thim; K Lynch-Devaney; D K Podolsky
Journal:  Gastroenterology       Date:  1995-08       Impact factor: 22.682

9.  Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract.

Authors:  M C Rio; M P Chenard; C Wolf; L Marcellin; C Tomasetto; R Lathe; J P Bellocq; P Chambon
Journal:  Gastroenterology       Date:  1991-02       Impact factor: 22.682

10.  Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats.

Authors:  M W Babyatsky; M deBeaumont; L Thim; D K Podolsky
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

View more
  15 in total

1.  Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis.

Authors:  Ludmila Khailova; Katerina Dvorak; Kelly M Arganbright; Melissa D Halpern; Toshi Kinouchi; Masako Yajima; Bohuslav Dvorak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

2.  Proliferative response in necrotising enterocolitis is insufficient to prevent disease progression.

Authors:  Daniela Vieten; Anthony Corfield; Pramila Ramani; Richard Spicer
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

Review 3.  Pathogenesis of necrotizing enterocolitis: modeling the innate immune response.

Authors:  Scott M Tanner; Taylor F Berryhill; James L Ellenburg; Tamas Jilling; Dava S Cleveland; Robin G Lorenz; Colin A Martin
Journal:  Am J Pathol       Date:  2014-11-04       Impact factor: 4.307

4.  Intestinal Epithelial Barrier Function and Necrotizing Enterocolitis.

Authors:  Elizabeth Managlia; Xiaocai Yan; Isabelle G De Plaen
Journal:  Newborn (Clarksville)       Date:  2022-03-31

5.  Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.

Authors:  Julie M Kneller; Thomas Ehlen; Jasenka P Matisic; Dianne Miller; Dirk Van Niekerk; Wan L Lam; Marco Marra; Rebecca Richards-Kortum; Michelle Follen; Calum Macaulay; Steven J M Jones
Journal:  Biomark Insights       Date:  2007-12-11

6.  Gene expression in Barrett's esophagus: laser capture versus whole tissue.

Authors:  Hashem B El-Serag; Zhannat Z Nurgalieva; Toni-Ann Mistretta; Milton J Finegold; Rhonda Souza; Susan Hilsenbeck; Chad Shaw; Gretchen Darlington
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

Review 7.  Necrotizing enterocolitis: a multifactorial disease with no cure.

Authors:  Kareena-L Schnabl; John-E Van Aerde; Alan-Br Thomson; Michael-T Clandinin
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

Review 8.  Engineering the Mucus Barrier.

Authors:  T L Carlson; J Y Lock; R L Carrier
Journal:  Annu Rev Biomed Eng       Date:  2018-06-04       Impact factor: 9.590

9.  Cellular localization, binding sites, and pharmacologic effects of TFF3 in experimental colitis in mice.

Authors:  Stine Kjellev; Lars Thim; Charles Pyke; Steen S Poulsen
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

Review 10.  Innate immune signaling in the pathogenesis of necrotizing enterocolitis.

Authors:  David J Hackam; Amin Afrazi; Misty Good; Chhinder P Sodhi
Journal:  Clin Dev Immunol       Date:  2013-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.